APA

Ahmed O. A., Elsebaey M. A., Fouad M. H. A., Elashry H., Elshafie A. I., Elhadidy A. A., Esheba N. E., Elnaggar M. H., Soliman S. & Abd-Elsalam S. (2018). Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. : Infection and drug resistance.

Chicago

Ahmed Ossama A, Elsebaey Mohamed A, Fouad Mohamed Hassan A, Elashry Heba, Elshafie Ahmed I, Elhadidy Ahmed A, Esheba Noha E, Elnaggar Mohammed H, Soliman Shaimaa and Abd-Elsalam Sherief. 2018. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. : Infection and drug resistance.

Harvard

Ahmed O. A., Elsebaey M. A., Fouad M. H. A., Elashry H., Elshafie A. I., Elhadidy A. A., Esheba N. E., Elnaggar M. H., Soliman S. and Abd-Elsalam S. (2018). Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. : Infection and drug resistance.

MLA

Ahmed Ossama A, Elsebaey Mohamed A, Fouad Mohamed Hassan A, Elashry Heba, Elshafie Ahmed I, Elhadidy Ahmed A, Esheba Noha E, Elnaggar Mohammed H, Soliman Shaimaa and Abd-Elsalam Sherief. Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. : Infection and drug resistance. 2018.